- Home
- AARD vs ANTX Comparison
AARD vs ANTX Comparison
Compare AARD & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AARD | ANTX |
|---|---|---|
| Founded | 2017 | 2017 |
| Country | United States | United States |
| Employees | 40 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.8M | 158.8M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | AARD | ANTX |
|---|---|---|
| Price | $6.35 | $4.68 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 1 |
| Target Price | ★ $15.29 | $2.00 |
| AVG Volume (30 Days) | 439.3K | ★ 442.7K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.35 | $1.00 |
| 52 Week High | $17.94 | $6.91 |
Technical Indicators
Market Signals| Indicator | AARD | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 58.05 | 51.33 |
| Support Level | $4.76 | $3.91 |
| Resistance Level | $11.37 | $5.13 |
| Average True Range (ATR) | 0.93 | 0.36 |
| MACD | 0.12 | -0.02 |
| Stochastic Oscillator | 52.06 | 46.09 |
Price Performance
Historical ComparisonAbout AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.